Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth and by blocking blood flow to the tumor. This phase II trial is studying how well
sorafenib works in treating patients with advanced or recurrent uterine cancer.